Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer

Cancer Science

Volumn 95, Issue 5, 2004, Pages 418-423

  Iba, Takahiro ^a   Kigawa, Junzo ^a   Kanamori, Yasunobu ^a   Itamochi, Hiroaki ^a   Oishi, Tetsuro ^a   Simada, Muneaki ^a   Uegaki, Kazunori ^a   Naniwa, Jun ^a   Terakawa, Naoki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; CARBOPLATIN; KI 67 ANTIGEN; MESSENGER RNA; MYC PROTEIN; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53;

ADULT; AGED; ANTIGEN DETECTION; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESPONSE; EPITHELIUM; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GYNECOLOGIC SURGERY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NICK END LABELING; ONCOGENE C MYC; OVARY CANCER; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROC CURVE; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENES, MYC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3042644525     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03225.x     Document Type: Article

References (34)

1. Ozols RF. Treatment of ovarian cancer: current status. Semin Oncol 1994; 21: 1-9.
2. Kigawa J, Minagawa M, Ishihara H, Kanamori Y, Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystoadenocarcinoma. Cancer 1993; 72: 804-8.
3. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-9.
4. Andrews PA, Velury S, Mann SC, Howell SB. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Res 1998; 48: 68-73.
5. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990; 2: 35-43.
6. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070-4.
7. Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. Glutathione S-transferase-pi expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer 1997; 79: 521-7.
8. Kasahara K, Fujiwara Y, Nishio K et al. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 1991; 51: 3237-42.
9. Kuwano M, Toh S, Uchimi T, Takano H, Kohno K, Wada M. Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 1999; 14: 123-31.
10. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-93.
11. Minagawa Y, Kigawa J, Itamochi H, Kanamori Y, Shimada M, Takahashi M, Terakawa N. Cisplatin-resistant HeLa cells are resistant to apoptosis via p53-dependent and -independent pathways. Jpn J Cancer Res 1999; 90: 1373-9.
12. Takahashi M, Kigawa J, Minagawa Y et al. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 2000; 36: 1863-8.
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
14. Baker VV, Borst MP, Dixon D, Hatch KD, Shingleton HM, Miller D. c-myc amplification in ovarian cancer. Gynecol Oncol 1990; 38: 340-2.
15. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-9.
16. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999; 19: 1-11.
17. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12: 2424-33.
18. Tsuji K, Mizumoto K, Sudo H, Kouyama K, Ogata E, Matsuoka M. p53-independent apoptosis is induced by the p19ARF tumor suppressor. Biochem Biophys Res Commun 2002; 295: 621-9.
19. Hemmati PG, Gillissen B, von Haefen C et al. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene 2002; 21: 3149-61.
20. Huang YH, Wu JY, Zhang Y, Wu MX. Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-kappaB/rel complexes. Oncogene 2002; 21: 6819-28.
21. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-18.
22. Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, Kamazawa S, Terakawa N. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 1999; 86: 1307-13.
23. Pelengaris S, Khan M. The many faces of c-myc. Arch Biochem Biophys 2003; 416: 129-36.
24. Tanner B, Hengstler JG, Luch A, Meinert R, Kreutz E, Arand M, Wilkens C, Hofmann M, Oesch F, Knapstein PG, Becker R. C-myc mRNA expression in epithelial ovarian carcinomas in relation to estrogen receptor status, metastatic spread, survival time, FIGO stage, and histologic grade and type. Int J Gynecol Pathol 1998; 17: 66-74.
25. Diebold J, Suchy B, Baretton GB, Blasenbreu S, Meier W, Schmidt M, Rabes H, Lohrs U. DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis. Virchows Arch 1996; 429: 221-7.
26. van Dam PA, Vergote IB, Lowe DG, Watson JV, van Damme P, van der Auwera JC, Shepherd JH. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. J Clin Pathol 1994; 47: 914-9.
27. Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, Arisio R, Giardina G, Sismondi P. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res 1995; 15: 1501-10.
28. Irie T, Kigawa J, Minagawa Y, Oishi T, Takahashi M, Shimada M, Kamazawa S, Sato S, Terakawa N. Alteration of a p53 gene status affects outcome of patients with recurrent ovarian cancer. Oncology 2000; 58: 237-41.
29. McCarthy N, Mercer J, Bennett M. Apoptotic proteins. p53 and c-myc related pathways. Cardiol Dis 2001; 19: 75-89.
30. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994; 265: 2091-3.
31. Juin P, Hueber AO, Littlewood T, Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev 1999; 13: 1367-81.
32. Lutz W, Leon J, Eilers M. Contributions of Myc to tumorigenesis. Biochim Biophys Acta 2002; 1602: 61-71.
33. Plisiecka-Halasa J, Karpinska G, Szymanska T, Ziolkowska I, Madry R, Timorek A, Debmak J, Ulanska M, Jedryka M, Chudecka-Glaz A, Klimek M, Rembiszewska A, Kraszewska E, Dybowski B, Markowska. J, Emerich J, Pluzanska A, Goluda M, Rzepka-Gorska I, Urbanski K, Zielinski J, Stelmachow J, Chrabowska M, Kupryjanczyk J. P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 2003; 14: 1078-85.
34. Sherr CJ, Webber JD. The ARF/p53 pathway. Carr Opin Genet Dev 2000; 10: 94-9.